SYDNEY (BUSINESS WIRE) #CMO AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of
AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).
SYDNEY (BUSINESS WIRE) AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing rad.
Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress